339 related articles for article (PubMed ID: 24256239)
1. The subtype I-F CRISPR-Cas system influences pathogenicity island retention in Pectobacterium atrosepticum via crRNA generation and Csy complex formation.
Richter C; Fineran PC
Biochem Soc Trans; 2013 Dec; 41(6):1468-74. PubMed ID: 24256239
[TBL] [Abstract][Full Text] [Related]
2. In vivo protein interactions and complex formation in the Pectobacterium atrosepticum subtype I-F CRISPR/Cas System.
Richter C; Gristwood T; Clulow JS; Fineran PC
PLoS One; 2012; 7(12):e49549. PubMed ID: 23226499
[TBL] [Abstract][Full Text] [Related]
3. Structural plasticity and in vivo activity of Cas1 from the type I-F CRISPR-Cas system.
Wilkinson ME; Nakatani Y; Staals RH; Kieper SN; Opel-Reading HK; McKenzie RE; Fineran PC; Krause KL
Biochem J; 2016 Apr; 473(8):1063-72. PubMed ID: 26929403
[TBL] [Abstract][Full Text] [Related]
4. Csy4 is responsible for CRISPR RNA processing in Pectobacterium atrosepticum.
Przybilski R; Richter C; Gristwood T; Clulow JS; Vercoe RB; Fineran PC
RNA Biol; 2011; 8(3):517-28. PubMed ID: 21519197
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the Type I-F CRISPR-Cas system by CRP-cAMP and GalM controls spacer acquisition and interference.
Patterson AG; Chang JT; Taylor C; Fineran PC
Nucleic Acids Res; 2015 Jul; 43(12):6038-48. PubMed ID: 26007654
[TBL] [Abstract][Full Text] [Related]
6. CRISPR RNA and anti-CRISPR protein binding to the
Hong S; Ka D; Yoon SJ; Suh N; Jeong M; Suh JY; Bae E
J Biol Chem; 2018 Feb; 293(8):2744-2754. PubMed ID: 29348170
[TBL] [Abstract][Full Text] [Related]
7. Spacer capture and integration by a type I-F Cas1-Cas2-3 CRISPR adaptation complex.
Fagerlund RD; Wilkinson ME; Klykov O; Barendregt A; Pearce FG; Kieper SN; Maxwell HWR; Capolupo A; Heck AJR; Krause KL; Bostina M; Scheltema RA; Staals RHJ; Fineran PC
Proc Natl Acad Sci U S A; 2017 Jun; 114(26):E5122-E5128. PubMed ID: 28611213
[TBL] [Abstract][Full Text] [Related]
8. Interference activity of a minimal Type I CRISPR-Cas system from Shewanella putrefaciens.
Dwarakanath S; Brenzinger S; Gleditzsch D; Plagens A; Klingl A; Thormann K; Randau L
Nucleic Acids Res; 2015 Oct; 43(18):8913-23. PubMed ID: 26350210
[TBL] [Abstract][Full Text] [Related]
9. Reconstitution of CRISPR adaptation in vitro and its detection by PCR.
Fagerlund RD; Ferguson TJ; Maxwell HWR; Opel-Reading HK; Krause KL; Fineran PC
Methods Enzymol; 2019; 616():411-433. PubMed ID: 30691653
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic chromosomal targeting by CRISPR/Cas systems can reshape bacterial genomes and expel or remodel pathogenicity islands.
Vercoe RB; Chang JT; Dy RL; Taylor C; Gristwood T; Clulow JS; Richter C; Przybilski R; Pitman AR; Fineran PC
PLoS Genet; 2013 Apr; 9(4):e1003454. PubMed ID: 23637624
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the Csm3-Csm4 subcomplex in the type III-A CRISPR-Cas interference complex.
Numata T; Inanaga H; Sato C; Osawa T
J Mol Biol; 2015 Jan; 427(2):259-73. PubMed ID: 25451598
[TBL] [Abstract][Full Text] [Related]
12. Requirements for a successful defence reaction by the CRISPR-Cas subtype I-B system.
Stoll B; Maier LK; Lange SJ; Brendel J; Fischer S; Backofen R; Marchfelder A
Biochem Soc Trans; 2013 Dec; 41(6):1444-8. PubMed ID: 24256235
[TBL] [Abstract][Full Text] [Related]
13. Foreign DNA acquisition by the I-F CRISPR-Cas system requires all components of the interference machinery.
Vorontsova D; Datsenko KA; Medvedeva S; Bondy-Denomy J; Savitskaya EE; Pougach K; Logacheva M; Wiedenheft B; Davidson AR; Severinov K; Semenova E
Nucleic Acids Res; 2015 Dec; 43(22):10848-60. PubMed ID: 26586803
[TBL] [Abstract][Full Text] [Related]
14. Cas1 and Cas2 From the Type II-C CRISPR-Cas System of
He Y; Wang M; Liu M; Huang L; Liu C; Zhang X; Yi H; Cheng A; Zhu D; Yang Q; Wu Y; Zhao X; Chen S; Jia R; Zhang S; Liu Y; Yu Y; Zhang L
Front Cell Infect Microbiol; 2018; 8():195. PubMed ID: 29951376
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-Cas systems and RNA-guided interference.
Barrangou R
Wiley Interdiscip Rev RNA; 2013; 4(3):267-78. PubMed ID: 23520078
[TBL] [Abstract][Full Text] [Related]
16. How type II CRISPR-Cas establish immunity through Cas1-Cas2-mediated spacer integration.
Xiao Y; Ng S; Nam KH; Ke A
Nature; 2017 Oct; 550(7674):137-141. PubMed ID: 28869593
[TBL] [Abstract][Full Text] [Related]
17. Hot and crispy: CRISPR-Cas systems in the hyperthermophile Sulfolobus solfataricus.
Zhang J; White MF
Biochem Soc Trans; 2013 Dec; 41(6):1422-6. PubMed ID: 24256231
[TBL] [Abstract][Full Text] [Related]
18. Modulating the Cascade architecture of a minimal Type I-F CRISPR-Cas system.
Gleditzsch D; Müller-Esparza H; Pausch P; Sharma K; Dwarakanath S; Urlaub H; Bange G; Randau L
Nucleic Acids Res; 2016 Jul; 44(12):5872-82. PubMed ID: 27216815
[TBL] [Abstract][Full Text] [Related]
19. Substrate generation for endonucleases of CRISPR/cas systems.
Zoephel J; Dwarakanath S; Richter H; Plagens A; Randau L
J Vis Exp; 2012 Sep; (67):. PubMed ID: 22986408
[TBL] [Abstract][Full Text] [Related]
20. Cutting it close: CRISPR-associated endoribonuclease structure and function.
Hochstrasser ML; Doudna JA
Trends Biochem Sci; 2015 Jan; 40(1):58-66. PubMed ID: 25468820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
